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The construction and characterization of vaccinia virus recombinants carrying the nucleocapsid (N) protein
gene of human respiratory syncytial (RS) virus are described. Recombinant viruses were constructed that
contained the N gene oriented either positively or negatively with respect to the 7.5-kilodalton vaccinia virus
promoter. In addition, a positively oriented recombinant was constructed that lacked an out-of-frame AUG
codon in the 5'-terminal noncoding region. In HEp-2 cells, both positive-orientation recombinants induced the
synthesis of a protein which comigrated with N protein and was precipitated by antisera to RS virus. Sera from
mice immunized with these recombinants specifically precipitated the RS virus N protein. Analysis of mRNA
and protein expressed from the recombinant N genes showed that deletion of the upstream AUG codon
markedly improved the efficiency of protein synthesis. Mice were vaccinated with the high-expressing
recombinant and subsequently challenged with live RS virus. The results of these experiments demonstrated
that the immune response to N protein afforded a significant degree of protection against RS virus disease.
Human respiratory syncytial (RS) virus, a paramyxovirus
of the pneumovirus taxon, is a leading cause of severe lower
respiratory tract infection in children. No safe and effective
vaccine is currently available for human use. Experimental
vaccination of children with inactivated RS virus actually
increased the severity of the disease (11). This, and the fact
that individuals may become reinfected with antigenically
related strains of RS virus at intervals of 2 to 3 years (9),
highlights the problem of stimulating and maintaining immu-
nity in the human host.
In an effort to dissect the role of individual RS virus
proteins in the pathogenesis of RS virus disease and to
analyze the various components of the immune response to
RS infection, vaccinia virus recombinant vectors have been
used to express individual RS virus genes in cell culture and
in experimental animals. Vaccinia virus recombinants carry-
ing DNA copies of the genes encoding the glycoprotein (G)
and fusion glycoprotein (F) of human RS virus have been
described (1, 6, 16, 26). Infection of mice (20, 26) or cotton
rats (6, 16) with recombinant viruses expressing either
protein elicited a strong humoral antibody response and
conferred significant protection against live-virus challenge.
However, studies with immunodeficient hosts show that a
functional cellular immune system assists in clearing RS
virus infections (7). It may also be significant that the
vaccine recently developed for use against bovine RS virus
is made from virus-infected bovine cells (22), rather than free
virus, and its potency could well be due to an ability to
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induce some kind of cell-mediated immune response. Inter-
estingly, the internal nucleocapsid (N) proteins of both
influenza (25, 30) and vesicular stomatitis (17) viruses are
major target antigens for cytotoxic T lymphocytes. It was of
interest, therefore, to determine whether the equivalent
nucleocapsid protein of RS virus would also be able to
stimulate a protective immune response. This paper de-
scribes (i) the construction of vaccinia virus recombinants
that carry the N protein gene of human RS virus, (ii) an
analysis of the RS virus-specific transcription and translation
products of these recombinant vectors in infected cells, and
(iii) a study of their efficacy as live-virus vaccines in mice. In
conjunction with this work, recent experiments with these
recombinants have shown that the N protein is recognized as
a target antigen by human and murine RS virus-primed
cytotoxic T lymphocytes (2).
MATERIALS AND METHODS
Vaccinia virus insertion plasmids. A cDNA copy of the
complete N gene of RS virus was made by fusing clones
N257 and N6-63 (4) at the XbaI site (D. Malinowski and R.
Pearson, unpublished data). A 1.6-kilobase (kb) AhaIlI
fragment from this construct, containing the N gene, was
cloned into the SminI site of a recombinant plasmid that
contained the vaccinia virus 7.5-kilodalton (kDa) promoter
in the EcoRI site of the thymidine kinase (TK) gene (20) to
produce vector pSL125 shown in Fig. 1A. Insertion of the
same DNA fragment in the opposite orientation generated
insertion plasmid pSL73 (not shown). Plasmid pAQ330 was
derived from pSL125 as described in the legend to Fig. 1B.
Routine manipulations were done by the method of Maniatis
et al. (14).
Recombinant vaccinia viruses. Homologous recombination
(13) was used to transfer the N gene and associated 7.5-kDa
promoter, contained in each of the insertion plasmids
pSL125, pSL73, and pAQ330, into the TK gene of vaccinia
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FIG. 1. (A) Structure of vaccinia virus insertion plasmid pSL125. Vaccinia virus sequences flanking the split TK gene are indicated by a
line of intermediate thickness: 7.5k pro denotes the 7.5-kDa vaccinia virus promoter (3). (B) Construction of pAQ330, a derivative of pSL1'5
containing a deletion in the 5'-terminal noncoding region of the N gene. Manipulations were performed on a copy of the N gene that had been
inserted into pGEM-1. This plasmid (pAQ176) was opened with BalmHI on the 5' side of the N gene. The ends of the DNA were resected with
Bal 31 exonuclease and made flush with T4 DNA polymerase. Terminal Hinidlll fragments were fractionated by agarose gel electrophoresis,
and an appropriate size class of fragments was cloned into pGEM-1 cut with Hiticll and Hintdlll. The Ba,nHI-HindIII N-gene fragment from
one such clone (pAQ329) was substituted for the homologous region of pSL125, to produce the desired vaccinia virus insertion plasmid,
pAQ330. To facilitate this final step, the extra Hindlll site in pSL125 was first destroyed by partially digesting the plasmid with Hindlll. filling
the ends with T4 DNA polymerase, and recircularizing. (C) Nucleotide sequence of pAQ330 across the site of the deletion: comparison with
the sequence of pSL125. The sequence of the BarnHI-HindllI fragment, end labeled at the BamtiHl site, was determined by the method of
Maxam and Gilbert (15).
virus (strain WR), the resulting recombinant viruses being
named VVN125, VVN73, and VVN333, respectively. Tk-
recombinants were selected by plaque assay in the presence
of 5-bromodeoxyuridine and identified by dot blot hybridiza-
tion by the procedure of Gillespie and Bresser (8). Viruses
were purified by one or two further plaque isolations, and
stocks were grown in HEp-2 cells.
Analysis of virus gene expression. Cytoplasmic RNA (27)
and protein were prepared from HEp-2 cells 20 to 22 h
postinfection with human RS virus (strain A2) or 4 h post-
infection with vaccinia virus and its recombinants. In studies
of RNA synthesis, late vaccinia virus functions were inhib-
ited by treating the cells with 100 pLg of cycloheximide per ml
at the time of infection. RNA was recovered by phenol
extraction, electrophoresed on 1.5% agarose gels containing
6 M urea at pH 3.5 (29), and blotted onto diazoben-
zyloxymethyl paper. Blots were hybridized with labeled
RNA probes transcribed in vitro from DNA inserted into
pGEM-1, using T7 or SP6 RNA polymerase. For protein
analyses, cells were lysed at 0°C in 0.5 ml, per 35-mm plate,
of 0.01 M Tris hydrochloride (pH 7.4)-66 mM EDTA-1%
Nonidet P-40-0.4% sodium deoxycholate, and the nuclei
were removed by centrifuging for 3 min in an Eppendorf
centrifuge. RS virus-specific proteins were immune precip-
itated and electrophoresed as described previously (28).
Vaccination and challenge of mice. Groups of five specific-
pathogen-free BALB/c mice were vaccinated with vaccinia
virus recombinants either intraperitoneally or intranasally
under anesthesia. Three weeks later, blood samples were
collected from the tail vein and assayed for antibody by
enzyme-linked immunosorbent assay using sonicated RS
virus-infected HEp-2 cells as antigen and goat anti-mouse
immunoglobulin G coupled to horseradish peroxidase (KPL
Laboratories, Inc., Gaithersburg, Md.) to detect RS virus-
specific mouse immunoglobulin. The mice were then chal-
lenged intranasally with 2 x 104 PFU of RS virus; after 5
days, they were killed and their lungs were assayed for virus
(24).
RESULTS
Structures of vaccinia virus recombinants. The N gene of

































FIG. 2. Positive-sense (A and B) and antisense (C and D) RNAs
expressed by the vaccinia virus recombinants. (A, B) HEp-2 cells
were infected as indicated, and cytoplasmic RNA was electropho-
resed on agarose-urea gels. Duplicate blots were probed with
labeled RNA complementary to either (A) an internal region of the
N gene, located between the HindIlI and RsaI sites, or (B) vaccinia
virus sequences upstream of the 7.5-kDa promoter. The map below
the gels shows the locations of the hybridization probes. Note that
this map is of the plus-sense recombinant vaccinia viruses VVN125
and VVN333; the DNA insert, represented by the thickened line,
was inverted in VVN73, and both insert and 7.5-kDa promoter are
missing in wild-type (wt) vaccinia virus. (C, D) The experiment
illustrated in (C) is an exact replica of that shown in (A) except that
promoter, was recombined into vaccinia virus, using inser-
tion plasmids of the type shown in Fig. 1A. This report
describes studies of three N-gene recombinants. Recombi-
nant VVN125, derived from PSL125 (Fig. 1A), contained the
N gene positively oriented behind the 7.5-kDa promoter.
Recombinant VVN73 contained the same DNA insert, but in
the opposite orientation. Recombinant VVN333, described
below, was identical to VVN125 except for a deletion in the
5'-terminal noncoding region of the N gene. In addition to
the complete 1,197-nucleotide N mRNA sequence (4), the
N-gene DNA fragment carried by recombinants VVN125
and VVN73 retained 30 base pairs of upstream RS virus
sequence derived from the region between the 1B and N
genes and 334 base pairs of pBR322 joined to the 3' end of
the N gene by an oligo(dC:dG) linker.
Preliminary studies (not shown) with recombinants
VVN125 and VVN73 showed that VVN125 induced the
synthesis of a protein which comigrated with N and which
was recognized by RS virus antisera. The quantity detected
was less than that seen in RS virus-infected cells. One
explanation for the low level of expression was suggested by
the nucleotide sequence of the 5'-terminal noncoding region
of the N gene (Fig. 1A, top). The junction between the
intergenic region and the start of the normal N message
creates an initiation codon, AUG (ATG in the DNA copy),
which is in a different reading frame from the N gene and
might be expected to inhibit translation of it. The unwanted
ATG sequence was removed by making a small deletion in
the 5' noncoding region of pSL125 (Fig. 1B). The nucleotide
sequence across the site of the deletion (Fig. 1C) confirmed
that the upstream ATG was eliminated, while the correct
initiation sites for transcription and translation were left
intact. This version of the N gene was also recombined into
vaccinia virus, generating the third recombinant, VVN333.
Analysis of recombinant transcripts. Transcription from
VVN125 and VVN333 was analyzed by Northern blot hy-
bridization. Figure 2A, B, C, and D shows blots of cytoplas-
mic RNA electrophoresed on agarose-urea gels. Hybridiza-
tion with a probe complementary to N mRNA (Fig. 2A)
revealed four species of RNA in RS virus-infected HEp-2
cells, which have been identified previously as the major
monocistronic N mRNA (length, 1.27 kb) and three longer
readthrough trapscripts (5). In cells infected with VVN125
and VVN333, several N transcripts were detected, the four
major species being between 0.8 and 2.0 kb long. Although
the patterns of RNAs made by these two recombinants were
similar, each species of VVN333 RNA migrated slightly
faster than its VVN125 counterpart, consistent with the
25-base-pair deletion that had been introduced in VVN333.
This observation confirms that all four RNA species con-
tained the initiation site for N-protein synthesis. We can also
be confident that none of the major transcripts originated
from the upstream TK promoter, since the low level of
readthrough from that promoter (Fig. 2B) shows that the
7.5-kDa promoter fragment acts as a strong terminator of
early transcription. We therefore conclude that all N-gene
transcripts of VVN125 and VVN333 started at the 7.5-kDa
promoter and terminated at four alternative locations. Fur-
thermore, three of the four mRNA species were long enough
to encode a complete N polypeptide. Curiously, VVN73 also
a positive-sense hybridization probe was used. A longer probe (D) of
the same polarity revealed a short transcript made by the antisense
recombinant VVN73, a map of which is shown at the bottom. Sizes

















FIG. 3. Synthesis of N protein by vaccinia virus recombinants.
HEp-2 cells were infected as indicated and labeled with [35SJmethio-
nine for 30 min prior to preparation of cytoplasmic extracts. RS
virus proteins were immune precipitated. where indicated, with (B)
bovine RS virus antiserum (Burroughs Wellcome) or (MAb) N-
specific monoclonal antibody (MAb 15) (21) and analyzed by elec-
trophoresis on 12.5%X( sodium dodecyl sulfate-polyacrylamide gels.
wt, wild type.
synthesized N RNA of positive sense early in infection,
despite the inverted orientation of its N gene with respect to
the 7.5-kDa promoter. However, these transcripts were
shorter than would be expected for a full-length N mRNA
(Fig. 2A).
Transcripts of negative sense were sought by using mRNA
sense hybridization probes. No RNA complementary to the
middle region of the N gene was detected in cells infected
with any of the vaccinia virus recombinants (Fig. 2C and D).
The band visible at the top of panel C represents minus-
strand RS virus genome. However, when the probe ex-
tended over the entire 1.6-kb insert (panel D), an RNA
species of approximately 0.4 kb was detected specifically in
cells infected with the negative-sense construct, VVN73.
This shows that the 7.5-kDa promoter did indeed drive
transcription of negative-sense RNA in recombinant
VVN73, although the product failed to extend as far as the N
gene.
Expression of N protein by recombinant vaccinia viruses.
Figure 3 shows that the translational activities of the two
positively oriented N recombinants, VVN125 and VVN333,
were very different from each other. HEp-2 cells infected
with VVN333 made large amounts of a 42-kDa protein that
comigrated with authentic N. This protein was precipitated
specifically by several RS virus antibody preparations, in-
cluding a polyclonal bovine RS virus serum ("B'' in Fig. 3)
and an N-specific monoclonal antibody ("MAb' '). This
protein was also detected in cells infected with VVN125, but
at <1/10 the level of VVN333. With the monoclonal anti-
body, an N-protein band was seen in the VVN125 track after
longer exposure than the one illustrated. The 42-kDa band
TABLE 1. Vaccination of mice with vaccinia virus recombinants
Mean Mean RS
Virus antibody virus titer Probability
Vaccine Route dose titer in in lungs + of
(PFU) serum + SD (log,0 difference'
SlgY,PFU/g ofSD(o11'wet tissue)1'
VVN125 Intraperi- 2 x 107 3.4 + 0.2 3.5 ± 0.3 0.068
toneal
None 1.5 4.2 ± 0.4
VVN333 Intraperi- 1 x 106 4.1 + 0.2 3.2 ± 0.3 0.0007
toneal
VVN333 Intranasal 1 x 1(6 4.2 + 0.3 3.4 ± 0.1 0.0001
None 1.5 4.2 ± 0.1
Enzyme-linked immunosorbent assay titer at 21 days after vaccination.
At 5 days after challenge (± standard deviation).
Probability of difference between vaccinated and control virus titers.
calculated by Student's t test.
was not seen in mock-infected cells or in cells infected with
wild-type vaccinia virus or the negative-sense recombinant
VVN73.
In addition to the major 42-kDa N protein, small amounts
of two shorter polypeptides of 24 and 25 kDa were seen.
These appeared to be products of the recombinant N gene,
since they were only found in recombinant-infected cells,
and were recognized by three different polyclonal RS virus
sera (data not shown). The 25-kDa polypeptide, seen in Fig.
3, was made in equal amounts by all three recombinants
independently of gene orientation and was presumably ex-
pressed from a cryptic vaccinia virus promoter rocated
within the N gene. The ability, noted earlier, of VVN73 to
make N-gene transcripts of positive sense is consistent with
this explanation. By contrast, the amounts of the 24-kDa
product varied, VVN125 making less than VVN333 (in the




FIG. 4. Immune precipitation of N protein by sera from vacci-
nated mice. HEp-2 cells were infected with RS virus and labeled
with [3H]Ieucine and [3Hlthreonine for 16 h before preparation of
cytoplasmic extracts. Virus proteins were precipitated with (lane 1)
gnotobiotic bovine hyperimmune antiserum. (lane 2) serum from
unvaccinated mice. (lane 3) serum from mice vaccinated with
recombinant VVN125 intraperitoneally. or (lane 4) serum from mice
vaccinated with VVN333 intraperitoneally or (lane 5) intranasally.
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former, the band could only be seen after longer exposure
than that illustrated) and VVN73 making none at all.
Response of mice to vaccination with recombinants. Previ-
ous work with the inbred BALB/c mouse system has shown
a protective role for the RS virus G and F proteins when
expressed individually from recombinant vaccinia virus vec-
tors (20, 26). We therefore used BALB/c mice to test the
efficacy of the N recombinants against live-virus challenge.
Mice were immunized with recombinant VVN125 or
VVN333 by the intraperitoneal or intranasal route. Three
weeks after immunization, mice were bled to assay for
serum antibody and the animals were then challenged by
intranasal inoculation of 2 x 104 PFU of RS virus. Enzyme-
linked immunosorbent assays demonstrated the presence of
RS virus-specific antibodies in the sera of mice 21 days after
vaccination (Table 1). Higher anti-RS virus titers were
present in the sera of animals vaccinated with VVN333 than
in those vaccinated with VVN125. The high-expressing
recombinant VVN333 generated 5-fold more RS antibody
than recombinant VVN125 even though the dose of VVN333
was 20-fold lower. This antiserum was specific for N protein
as shown by its ability to specifically immunoprecipitate N
protein from lysates of RS virus-infected cells (Fig. 4).
After challenge with RS virus by the intranasal route. mice
that had been vaccinated with recombinant VVN333 showed
significantly lower titers of RS virus in their lungs compared
with unvaccinated controls (Table 1). These results show
that expression of high levels of RS virus N protein can
provide partial protection of the lower respiratory tract
against live-virus challenge.
DISCUSSION
Vaccinia virus provides a uniquely versatile eucaryotic
expression vector because of its high immunogenicity. its
broad host range, and the nondefective nature of its recom-
binants. These properties enable one to examine at the
molecular level the behavior of individual recombinant vi-
ruses in cultured cells and then to study the immune re-
sponses to the same recombinants by inoculation of experi-
mental animals. We have used this approach to study both
the immunogenicity of several individual RS virus proteins
and the response of different branches of the immune system
(2, 20. 26).
In the work described above, we successfully expressed
the N-protein gene of human RS virus from vaccinia virus
recombinants both in infected cells in culture and in inocu-
lated mice. A potential problem in expressirig foreign genes
from early vaccinia virus promoters is exemplified by the
fact that only one of five 7.5-kDa promoter transcripts ended
at an authentic vaccinia virus termination site. Thus, only
the longest (2.0 kb) N mRNA made by VVN125 and
VVN333 (Fig. 2A) extended as far as the 3' end of the TK
gene. the others ending at cryptic termination sites within
the inserted DNA. Transcription from the 7.5-kDa promoter
in the negative-sense construct. VVN73, also ended prema-
turely. The termination signal for early vaccinia virus tran-
scription was recently shown to have the consensus se-
quence TTTTTNT, where N is preferentially A (18). The
signal appears once in the N gene, at nucleotide 680 in the
mRNA sequence (4), in the form TTTTTGT. The predicted
size of a recombinant transcript terminating at this site
coincides with the observed size of the smallest N-specific
mRNA made by VVN125 and VVN333 (allowing for the fact
that termination occurs 50 to 70 nucleotides downstream
from the signal). It is also easy to explain how a 3'-terminal
poly(A) tract can completely block synthesis of antisense
RNA as we have observed before (1), since its complement
would be recognized as the reiterated termination signal
TTTTTTT.
The availability of two vaccinia virus recombinants dif-
fering only in the 5'-terminal noncoding region of the N gene
provided an opportunity to test the translational effect of an
upstream initiation codon in a vaccinia virus mRNA. This
AUG codon lies within a sequence favorable for initiating
translation and, according to the ribosome-scanning model
(12). would be expected to depress N-protein synthesis
strongly. Until now, however, it has not been certain
whether the rules of the scanning model apply to vaccinia
virus: the fact that late vaccinia virus messages tend to be
polycistronic and often lack a favorable upstream consensus
sequence at their initiation sites (19) suggests that they may
not. Our analyses of RNA and protein expressed by the N
genes of VVN1125 and VVN333 show that removal of an
upstream AUG codon can increase significantly the transla-
tional activity of a vaccinia virus mRNA, in accordance with
the scanning model.
Vaccination with recombinant VVN333 resulted in signif-
icantly reduced RS virus titers in the lungs of mice following
live-virus challenge. This protection. however, was not as
great as that provided by vaccination with recombinants that
expressed the F or G surface glycoprotein (20, 26). It is
unlikely that the humoral antibody generated against the
nucleoprotein played a major role in this protection since the
nucleocapsid protein is an internal viral protein and the
N-specific mouse antisera failed to neutralize RS virus in
vitro. Moreover, passive transfer of monoclonal antibodies
to N protein did not protect mice (23). However, it has been
shown recently that infection with recombinant VVN 125
confers on autologous target cells the ability to be lysed by
human or murine cytotoxic T cells induced by RS virus
infection (2). Moreover, murine cytotoxic T cells are in-
duced by recombinants carrying the N gene (R. M.
Pemberton, M. J. Cannon, P. J. M. Openshaw. L. A. Ball,
G. W. Wertz. and B. A. Askonas. submitted for publication)
so it seems likely that this cell-mediated immune response is
primarily responsible for the partial protection seen in vac-
cinated mice.
Cytotoxic T cells have previously been implicated in
clearing RS virus infections (7). and this role has recently
been confirmed by experiments in which primed T cells were
passively transferred into nude athymic. or irradiated, mice
persistently infected with RS virus (M. J. Cannon, E. J.
Stott, G. Taylor. and B. A. Askonas, unpublished data). The
results in this paper show that it is also possible, in principle,
to exploit the cellular immune system prophylactically.
Although the degree of protection provided by the N-gene
recombinant was less than that provided by recombinants
carrying the RS virus genes for the G or F glycoprotein (6,
16. 20. 26), there are potential advantages to using an
internal viral antigen to stimulate a cellular immune re-
sponse, one of which is that it would be cross-typic. A
double recombinant that expresses both the N protein and a
surface glycoprotein of RS virus might elicit the optimum
protective response. Such a recombinant has been con-
structed (L. A. Ball, A. M. Q. King, and G. W. Wertz,
manuscript in preparation) and will shortly be tested for its
efficacy as a vaccine.
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